WGU D116 Advanced Pharmacology:
The Definitive 2026/2027 OA & Exam
Mastery Guide –Verified Questions
with Correct Answers, Comprehensive
Clinical Rationales, and A+ Graded
Study Companion
Q1. Which of the following best describes pharmacokinetics?
A) The study of drug effects on the body
B) The study of drug absorption, distribution, metabolism, and
excretion (ADME)
C) The study of drug toxicity
D) The study of drug interactions
Answer: B
Rationale: Pharmacokinetics is "what the body does to the drug" and
encompasses the four processes of Absorption, Distribution, Metabolism,
and Excretion (ADME). Pharmacodynamics, in contrast, is "what the drug
does to the body" – the study of drug effects and mechanisms of action.
Q2. The "first-pass effect" refers to:
A) The rapid onset of action of intravenous drugs
B) The metabolism of a drug in the liver before it reaches systemic
circulation
, C) The excretion of a drug via the kidneys immediately after
absorption
D) The binding of a drug to plasma proteins
Answer: B
Rationale: The first-pass effect occurs when a drug is metabolized in the
liver before reaching systemic circulation, which reduces the bioavailability
of orally administered drugs. Drugs like nitroglycerin and morphine require
higher oral doses or alternative routes to bypass this effect.
Q3. Bioavailability is defined as:
A) The speed of drug absorption
B) The fraction of an administered dose that reaches systemic
circulation unchanged
C) The volume of distribution
D) The half-life of the drug
Answer: B
Rationale: Bioavailability measures how much of an administered dose
reaches the bloodstream unchanged. Intravenous (IV) administration has
100% bioavailability because it bypasses absorption and first-pass
metabolism. Oral bioavailability is reduced by first-pass metabolism and
incomplete absorption.
Q4. Which route of administration has the highest bioavailability and
fastest onset of action?
A) Oral
B) Subcutaneous
C) Intravenous (IV)
D) Intramuscular (IM)
,Answer: C
Rationale: IV administration bypasses absorption barriers and first-pass
metabolism, delivering 100% of the dose directly into systemic circulation.
It also provides the most rapid onset of action and is used in emergencies
requiring immediate drug effect.
Q5. Which routes of administration avoid first-pass metabolism?
(Select all that apply)
A) Oral
B) Sublingual
C) Intravenous
D) Subcutaneous
E) Rectal
Answer: B, C, D
Rationale: Sublingual drugs are absorbed directly into systemic circulation
via the oral mucosa, bypassing the liver and first-pass metabolism. IV
administration delivers drugs directly into the bloodstream, completely
bypassing absorption and first-pass effects. Subcutaneous and IM routes
also bypass first-pass metabolism. Oral and rectal routes are subject to
first-pass metabolism.
Q6. Which CYP enzyme is responsible for metabolizing the largest
number of drugs (approximately 50%)?
A) CYP2D6
B) CYP1A2
C) CYP3A4
D) CYP2C9
Answer: C
Rationale: CYP3A4 metabolizes approximately 50% of all drugs, including
, statins, calcium channel blockers, macrolide antibiotics, and many others. It
is located in both the liver and small intestine and is involved in numerous
drug-drug interactions.
Q7. A patient with hepatic impairment is prescribed a medication
metabolized by the CYP3A4 enzyme. Which pharmacokinetic process is
most affected?
A) Absorption
B) Distribution
C) Metabolism
D) Excretion
Answer: C
Rationale: Hepatic impairment primarily alters metabolism (Phase I
reactions via CYP enzymes like CYP3A4). This can lead to a prolonged drug
half-life and an increased risk of toxicity. Absorption and distribution are
affected by other factors like blood flow and protein binding, while
excretion is primarily a renal function.
Q8. A patient with renal impairment is prescribed a medication
primarily eliminated by the kidneys. The nurse anticipates which
pharmacokinetic change?
A) Increased absorption
B) Decreased distribution
C) Increased drug half-life
D) Decreased drug half-life
Answer: C
Rationale: Renal impairment reduces drug excretion, prolonging half-life
and increasing the risk of accumulation and toxicity. Dose adjustments are
often required.
The Definitive 2026/2027 OA & Exam
Mastery Guide –Verified Questions
with Correct Answers, Comprehensive
Clinical Rationales, and A+ Graded
Study Companion
Q1. Which of the following best describes pharmacokinetics?
A) The study of drug effects on the body
B) The study of drug absorption, distribution, metabolism, and
excretion (ADME)
C) The study of drug toxicity
D) The study of drug interactions
Answer: B
Rationale: Pharmacokinetics is "what the body does to the drug" and
encompasses the four processes of Absorption, Distribution, Metabolism,
and Excretion (ADME). Pharmacodynamics, in contrast, is "what the drug
does to the body" – the study of drug effects and mechanisms of action.
Q2. The "first-pass effect" refers to:
A) The rapid onset of action of intravenous drugs
B) The metabolism of a drug in the liver before it reaches systemic
circulation
, C) The excretion of a drug via the kidneys immediately after
absorption
D) The binding of a drug to plasma proteins
Answer: B
Rationale: The first-pass effect occurs when a drug is metabolized in the
liver before reaching systemic circulation, which reduces the bioavailability
of orally administered drugs. Drugs like nitroglycerin and morphine require
higher oral doses or alternative routes to bypass this effect.
Q3. Bioavailability is defined as:
A) The speed of drug absorption
B) The fraction of an administered dose that reaches systemic
circulation unchanged
C) The volume of distribution
D) The half-life of the drug
Answer: B
Rationale: Bioavailability measures how much of an administered dose
reaches the bloodstream unchanged. Intravenous (IV) administration has
100% bioavailability because it bypasses absorption and first-pass
metabolism. Oral bioavailability is reduced by first-pass metabolism and
incomplete absorption.
Q4. Which route of administration has the highest bioavailability and
fastest onset of action?
A) Oral
B) Subcutaneous
C) Intravenous (IV)
D) Intramuscular (IM)
,Answer: C
Rationale: IV administration bypasses absorption barriers and first-pass
metabolism, delivering 100% of the dose directly into systemic circulation.
It also provides the most rapid onset of action and is used in emergencies
requiring immediate drug effect.
Q5. Which routes of administration avoid first-pass metabolism?
(Select all that apply)
A) Oral
B) Sublingual
C) Intravenous
D) Subcutaneous
E) Rectal
Answer: B, C, D
Rationale: Sublingual drugs are absorbed directly into systemic circulation
via the oral mucosa, bypassing the liver and first-pass metabolism. IV
administration delivers drugs directly into the bloodstream, completely
bypassing absorption and first-pass effects. Subcutaneous and IM routes
also bypass first-pass metabolism. Oral and rectal routes are subject to
first-pass metabolism.
Q6. Which CYP enzyme is responsible for metabolizing the largest
number of drugs (approximately 50%)?
A) CYP2D6
B) CYP1A2
C) CYP3A4
D) CYP2C9
Answer: C
Rationale: CYP3A4 metabolizes approximately 50% of all drugs, including
, statins, calcium channel blockers, macrolide antibiotics, and many others. It
is located in both the liver and small intestine and is involved in numerous
drug-drug interactions.
Q7. A patient with hepatic impairment is prescribed a medication
metabolized by the CYP3A4 enzyme. Which pharmacokinetic process is
most affected?
A) Absorption
B) Distribution
C) Metabolism
D) Excretion
Answer: C
Rationale: Hepatic impairment primarily alters metabolism (Phase I
reactions via CYP enzymes like CYP3A4). This can lead to a prolonged drug
half-life and an increased risk of toxicity. Absorption and distribution are
affected by other factors like blood flow and protein binding, while
excretion is primarily a renal function.
Q8. A patient with renal impairment is prescribed a medication
primarily eliminated by the kidneys. The nurse anticipates which
pharmacokinetic change?
A) Increased absorption
B) Decreased distribution
C) Increased drug half-life
D) Decreased drug half-life
Answer: C
Rationale: Renal impairment reduces drug excretion, prolonging half-life
and increasing the risk of accumulation and toxicity. Dose adjustments are
often required.
